samedan logo
 
 
spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

CPhI Worldwide: TE-ring remains firmly attached to the dropper bottle in line with FDA requirements

Gerresheimer AG

Niels Düring will be at booth 4.2 D02 at the CPhl, Frankfurt from October 24-26

Düsseldorf/Frankfurt, October 24, 2017 – It is often only minor improvements that make a product ideal to use. The TE-ring fixed to the type A eye-dropper bottle in accordance with the new FDA regulations is one good example.

"It’s often the technical details that add the finishing touches to packaging," says Niels Düring, Global Executive Vice President at Gerresheimer Plastic Packaging, who, with the help of his team, will showcase an extensive portfolio of plastic primary packaging for solids and liquids to existing and potential customers at booth 4.2 D02 at the CPhl in Frankfurt (Germany) from October 24-26.

TE-ring – now firmly attached to the bottle
The US Food and Drug Administration (FDA) now stipulate that the TE-ring must be firmly attached to the bottle. This product change was very easy to make, owing to experience with the type B dropper bottle, which already has a fixed TE-ring. Only minor adjustments were made to the design, while the dimensions, properties, and the materials are the same. The bottle and the dropper are made from LDPE and the cap from HDPE. The existing type A dropper bottles can therefore be used for stability tests.

Production of US dropper bottles with a fixed TE-ring will be operational in Q3, 2017 and production will besides Poland also be produced out of both India and US.

Gerresheimer produces type A dropper bottles holding 2-360 ml under clean-room conditions. Depending on the size of the container, they are produced using the injection blow molding (IBM) or the extrusion blow molding (EBM) process. Radiation or ETO sterilization is possible on request. All caps protect the original contents and can also be supplied with a child-proof screw cap.

You can find more information at www.gerresheimer.com

Plastic primary packaging for pharmaceuticals

About Gerresheimer
Gerresheimer is a leading global partner to the pharma and healthcare industry. With specialty glass and plastic products, the Company contributes to health and well-being. Gerresheimer operates worldwide and its approximately 10,000 employees manufacture products in local markets, close to its customers. With plants in Europe, North America, South America and Asia, Gerresheimer generates revenues of around EUR 1.4 bn. The company’s comprehensive product portfolio includes pharmaceutical packaging and products for the safe, simple administration of medicines: insulin pens, inhalers, prefillable syringes, injection vials, ampoules, bottles and containers for liquid and solid medicines with closure and safety systems as well as packaging for the cosmetics industry.

Press Contact

Jens Kürten
Group Senior Director Communication & Marketing
Phone +49 211 6181-250
Fax +49 211 6181-241
E-mail j.kuerten@gerresheimer.com

Marion Stolzenwald
Senior Manager Corporate Communication
Phone +49 211 6181-246
Fax +49 211 6181-241
E-mail m.stolzenwald@gerresheimer.com
phone +49-(0)211/61 81-00
email info@gerresheimer.com
web www.gerresheimer.com
email Klaus-Bungert-Str. 4, 40468 Duesseldorf, Germany
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Corning and Gerresheimer Collaborate to Deliver New Corning Valor™ Glass to the Pharmaceutical Packaging Market

Duesseldorf, October 24, 2017. Corning Incorporated (NYSE: GLW) and Gerresheimer announce that they are accelerating the supply of Corning Valor™ Glass to the pharmaceutical industry.
More info >>


White Papers

Overcoming research challenges with Adaptive Trials

PCI Pharma Services

There has been cause for concern within the pharmaceutical industry over the last five years, regarding increasing research and development costs, combined with a fall in the number of new drugs brought to market. In an attempt to overcome this issue there has been a significant rise in the use of adaptive clinical trial designs, whilst saving time and money as well as facilitating more effective decision making. One of the biggest challenges that pharmaceutical companies have experienced has been delivering compliant clinical trials supplies across diverse patient populations in the relatively short timeframes that adaptive trial designs require, remaining focused on ensuring that patient compliance and product quality is in no way compromised. This demand has led to the launch of fast response services that support Research and Development in responding to changing dosing regimens mid-trial.
More info >>

Industry Events

Global Bioproduction Summit, 5th-6th February 2018

5-6 February 2018, Hilton San Diego Resort & Spa, CA

After 15 years in Europe, the Global Bioproduction Summit moved to its new home of San Diego in 2016. The Bioproduction Summit delves deep into the world of biological production.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement